Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | DPP4 | P27487 | 5/20 | 0.44 |
| ▸ | FAP | Q12884 | 1/20 | 0.44 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.44 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 2/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL692548 | 1.00 | KMT2A (0.48) | KMT2AALDH1A1CYP3A4CYP2C19DPP4 | |
| SCHEMBL268274 | 1.00 | KMT2A (0.48) | KMT2AALDH1A1CYP3A4CYP2C19DPP4 | |
| Hydrochloric Acid SCHEMBL1068706 | 0.98 | KMT2A (0.47) | KMT2AALDH1A1CYP3A4CYP2C19DPP4 | |
| Hydrochloric Acid SCHEMBL30831586 | 0.98 | KMT2A (0.47) | KMT2AALDH1A1CYP3A4CYP2C19DPP4 | |
| Hydrochloric Acid SCHEMBL5561971 | 0.98 | KMT2A (0.47) | KMT2AALDH1A1CYP3A4CYP2C19DPP4 | |
| Hydrochloric Acid SCHEMBL5561964 | 0.98 | KMT2A (0.47) | KMT2AALDH1A1CYP3A4CYP2C19DPP4 | |
| SCHEMBL7244017 | 0.94 | ALDH1A1 (0.47) | KMT2AALDH1A1CYP3A4CYP2C19DPP4 | |
| SCHEMBL7342562 | 0.86 | ALDH1A1 (0.48) | KMT2AALDH1A1DPP4FAPDPP8 | |
| SCHEMBL20543771 | 0.86 | ALDH1A1 (0.48) | KMT2AALDH1A1DPP4FAPDPP8 | |
| SCHEMBL21117726 | 0.86 | ALDH1A1 (0.48) | KMT2AALDH1A1DPP4FAPDPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11427552-B2 | Heterocyclic compounds useful in the treatment of disease | EPIGEN BIOSCIENCES, INC. (US) | 2022-08-30 | — | — | US | disclosed |
| CN-105142635-B | Heterocyclic compounds useful for the treatment of diseases | 艾匹根生物技术有限公司 | 2021-07-27 | — | — | CN | disclosed |
| EP-2988743-B1 | HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DISEASE | EPIGEN BIOSCIENCES INC (US) | 2020-12-09 | — | — | EP | disclosed |
| US-20200181099-A1 | Heterocyclic Compounds Useful In The Treatment Of Disease | EPIGEN BIOSCIENCES, INC. (US) | 2020-06-11 | — | — | US | disclosed |
| US-10669242-B2 | Clostridium difficile toxin inhibitors | Venenum Biodesign, LLC (US) | 2020-06-02 | — | — | US | disclosed |
| US-10570103-B2 | Heterocyclic compounds useful in the treatment of disease | EPIGEN BIOSCIENCES, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-20190194147-A1 | Novel Clostridium Difficile Toxin Inhibitors | Venenum Biodesign, LLC (US) | 2019-06-27 | — | — | US | disclosed |
| US-20190135767-A1 | Heterocyclic Compounds Useful In The Treatment Of Disease | EPIGEN BIOSCIENCES, INC. (US) | 2019-05-09 | — | — | US | disclosed |
| US-20180297962-A1 | Heterocyclic Compounds Useful In The Treatment of Disease | EPIGEN BIOSCIENCES, INC. (US) | 2018-10-18 | — | — | US | disclosed |
| US-10000459-B2 | Heterocyclic compounds useful in the treatment of disease | EPIGEN BIOSCIENCES, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| WO-2014145873-A2 | HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DISEASE | EPIGEN BIOSCIENCES, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| US-8133907-B2 | Type II diabetes, obesity, hyperglycemia and a lipid disorder selected from dyslipidemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low HDL and high LDL; additionally comprising metformin | ELI LILLY AND COMPANY (US) | 2012-03-13 | — | — | US | disclosed |
| EP-1912946-B1 | PYRIDINE DERIVATIVES AS DIPEPTEDYL PEPTIDASE INHIBITORS | LILLY CO ELI (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20080214616-A1 | Pyridine Derivatives as Dipeptedyl Peptidase Inhibitors | ELI LILLY AND COMPANY | 2008-09-04 | — | — | US | disclosed |
| EP-1912946-A1 | PYRIDINE DERIVATIVES AS DIPEPTEDYL PEPTIDASE INHIBITORS | Eli Lilly and Company (US) | 2008-04-23 | — | — | EP | disclosed |
| US-20070197522-A1 | Dpp-iv inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2007-08-23 | — | — | US | disclosed |
| US-20070197522-A1 | Dpp-iv inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2007-08-23 | — | — | US | disclosed |
| US-20070197522-A1 | Dpp-iv inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2007-08-23 | — | — | US | disclosed |
| WO-2007015767-A1 | PYRIDINE DERIVATIVES AS DIPEPTEDYL PEPTIDASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2007-02-08 | — | — | WO | disclosed |
| WO-2005095343-A1 | DPP-IV INHIBITORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135767-A1 | Heterocyclic Compounds Useful In The Treatment Of Disease | LPAR1, LPAR2, LPAR4 | KMT2A 3283/4885ALDH1A1 2204/4885CYP3A4 3886/4885 |
| US-20080214616-A1 | Pyridine Derivatives as Dipeptedyl Peptidase Inhibitors | DPP4, DPP3, DPP7 | KMT2A 3516/4885ALDH1A1 557/4885CYP3A4 21/4885 |
| US-20180297962-A1 | Heterocyclic Compounds Useful In The Treatment of Disease | LPAR1, LPAR4, LPAR2 | KMT2A 3389/4885ALDH1A1 1649/4885CYP3A4 3283/4885 |
| US-20190194147-A1 | Novel Clostridium Difficile Toxin Inhibitors | GABRA5, GABRA1, GABRA4 | KMT2A 2401/4885ALDH1A1 2381/4885CYP3A4 127/4885 |
| US-10000459-B2 | Heterocyclic compounds useful in the treatment of disease | LPAR1, LPAR4, LPAR3 | KMT2A 2961/4885ALDH1A1 1693/4885CYP3A4 2983/4885 |
| US-20070197522-A1 | Dpp-iv inhibitors | DPP7, DPP4, DPP3 | KMT2A 3141/4885ALDH1A1 2070/4885CYP3A4 267/4885 |
| US-11427552-B2 | Heterocyclic compounds useful in the treatment of disease | LPAR1, LPAR4, LPAR3 | KMT2A 2961/4885ALDH1A1 1693/4885CYP3A4 2983/4885 |
| US-10669242-B2 | Clostridium difficile toxin inhibitors | GABRA5, GABRA1, GABBR2 | KMT2A 2561/4885ALDH1A1 1908/4885CYP3A4 86/4885 |
| US-20200181099-A1 | Heterocyclic Compounds Useful In The Treatment Of Disease | LPAR1, LPAR4, LPAR3 | KMT2A 2961/4885ALDH1A1 1693/4885CYP3A4 2983/4885 |
| US-10570103-B2 | Heterocyclic compounds useful in the treatment of disease | LPAR1, LPAR2, LPAR4 | KMT2A 3283/4885ALDH1A1 2204/4885CYP3A4 3886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.